Giulia Pasello

4.8k total citations
165 papers, 2.0k citations indexed

About

Giulia Pasello is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Giulia Pasello has authored 165 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Pulmonary and Respiratory Medicine, 86 papers in Oncology and 22 papers in Molecular Biology. Recurrent topics in Giulia Pasello's work include Lung Cancer Treatments and Mutations (66 papers), Occupational and environmental lung diseases (39 papers) and Lung Cancer Research Studies (37 papers). Giulia Pasello is often cited by papers focused on Lung Cancer Treatments and Mutations (66 papers), Occupational and environmental lung diseases (39 papers) and Lung Cancer Research Studies (37 papers). Giulia Pasello collaborates with scholars based in Italy, Spain and United States. Giulia Pasello's co-authors include Pierfranco Conté, Laura Bonanno, Valentina Guarneri, Adolfo Favaretto, Alberto Pavan, Ilaria Attili, Loredana Urso, Fiorella Calabrese, Alessandro Dal Maso and Lorenzo Calvetti and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Giulia Pasello

153 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Giulia Pasello Italy	23	1.1k	1.1k	510	349	207	165	2.0k
Atsushi Horiike Japan	28	1.3k 1.2×	1.3k 1.2×	604 1.2×	391 1.1×	146 0.7×	107	2.1k
Puyuan Xing China	22	1.0k 0.9×	1.2k 1.1×	461 0.9×	295 0.8×	151 0.7×	149	1.7k
Kai Li China	23	675 0.6×	1.2k 1.1×	477 0.9×	341 1.0×	242 1.2×	95	1.8k
Francesco Facchinetti Italy	25	1.2k 1.1×	1.1k 1.1×	827 1.6×	386 1.1×	161 0.8×	79	2.1k
Takehito Shukuya Japan	29	1.5k 1.4×	1.4k 1.3×	610 1.2×	438 1.3×	243 1.2×	130	2.5k
M. Duruisseaux France	21	1.0k 0.9×	1.0k 1.0×	413 0.8×	305 0.9×	102 0.5×	105	1.6k
Motoko Tachihara Japan	21	1.2k 1.1×	1.1k 1.1×	443 0.9×	249 0.7×	288 1.4×	109	1.9k
Katsuhiro Masago Japan	25	1.5k 1.4×	1.2k 1.1×	453 0.9×	324 0.9×	162 0.8×	119	2.1k
Alessandro Leonetti Italy	18	1.2k 1.1×	1.1k 1.0×	848 1.7×	424 1.2×	138 0.7×	54	2.0k
Saiama N. Waqar United States	29	1.9k 1.7×	1.7k 1.6×	654 1.3×	551 1.6×	310 1.5×	143	2.9k

Countries citing papers authored by Giulia Pasello

Since Specialization

Citations

This map shows the geographic impact of Giulia Pasello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giulia Pasello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giulia Pasello more than expected).

Fields of papers citing papers by Giulia Pasello

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giulia Pasello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giulia Pasello. The network helps show where Giulia Pasello may publish in the future.

Co-authorship network of co-authors of Giulia Pasello

This figure shows the co-authorship network connecting the top 25 collaborators of Giulia Pasello. A scholar is included among the top collaborators of Giulia Pasello based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giulia Pasello. Giulia Pasello is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Buja, Alessandra, Massimo Rugge, Manuel Zorzi, et al.. (2025). NON-SMALL-CELL LUNG CANCER: Real-World Population-Based Cohorts’ Study. Cancers. 17(4). 648–648.

Dingemans, Anne‐Marie C., Alessandro Dal Maso, Valentina Guarneri, et al.. (2025). Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort. European Journal of Cancer. 226. 115595–115595. 1 indexed citations

Ferro, Alessandra, Michele Bottosso, Maria Vittoria Dieci, et al.. (2024). Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives. Critical Reviews in Oncology/Hematology. 203. 104479–104479. 8 indexed citations

Ferro, Alessandra, et al.. (2024). The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies. Critical Reviews in Oncology/Hematology. 196. 104295–104295. 29 indexed citations

Bria, Emilio, José Luís Costa, Claudio Sini, et al.. (2024). 1283P Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database. Annals of Oncology. 35. S818–S818. 1 indexed citations

Pasello, Giulia, Alberto Pavan, M. Nuzzo, et al.. (2024). Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis. Frontiers in Oncology. 14. 3 indexed citations

Pasello, Giulia, Alessandro Del Conte, Fabiana Letizia Cecere, et al.. (2024). Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World. The Oncologist. 29(7). 596–608. 2 indexed citations

Malapelle, Umberto, Francesco Passiglia, Francesco Pepe, et al.. (2024). The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database. Lung Cancer. 191. 107787–107787. 2 indexed citations

Rossi, Giulio, Luisella Righi, Francesca Barbisan, et al.. (2024). BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report. Journal of Personalized Medicine. 14(4). 394–394. 1 indexed citations

10.

Malapelle, Umberto, Fabio Pagni, Filippo Fraggetta, et al.. (2023). Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group. Critical Reviews in Oncology/Hematology. 193. 104217–104217. 7 indexed citations

11.

Santarpía, Mariacarmela, et al.. (2023). Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need. International Journal of Molecular Sciences. 24(10). 8878–8878. 17 indexed citations

12.

Pasello, Giulia, Loredana Urso, Ilaria Cavallari, et al.. (2023). 2020P Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study. Annals of Oncology. 34. S1073–S1074. 1 indexed citations

13.

Bonanno, Laura, Davide Massa, M. Nuzzo, et al.. (2023). Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting. The Oncologist. 29(1). e118–e130. 6 indexed citations

14.

Dell’Amore, Andrea, Federica Pezzuto, Fiorella Calabrese, et al.. (2023). Microscopical Variables and Tumor Inflammatory Microenvironment Do Not Modify Survival or Recurrence in Stage I-IIA Lung Adenocarcinomas. Cancers. 15(18). 4542–4542. 1 indexed citations

15.

Pasello, Giulia, Giorgio Pigato, Loredana Urso, et al.. (2023). 2021P Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study. Annals of Oncology. 34. S1074–S1074. 1 indexed citations

16.

Ferro, Alessandra, Matteo Sepulcri, Marco Schiavon, et al.. (2022). The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments. Cancers. 14(22). 5700–5700. 13 indexed citations

17.

Maso, Alessandro Dal, Alessandra Ferro, Sara Pilotto, et al.. (2021). Real-World Data on Treatment Outcomes in EGFR -Mutant Non-Small-Cell Lung Cancer Patients Receiving Osimertinib in Second or Further Lines. Future Oncology. 17(19). 2513–2527. 8 indexed citations

18.

Maso, Alessandro Dal, et al.. (2020). Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers. 12(5). 1303–1303. 6 indexed citations

19.

Maso, Alessandro Dal, et al.. (2019). Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?. Critical Reviews in Oncology/Hematology. 138. 87–103. 17 indexed citations

20.

Maso, Alessandro Dal, Elisa Roca, Sara Pilotto, et al.. (2019). Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clinical Lung Cancer. 21(1). 1–14.e3. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact